A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
for Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Drug: Navlimetostat
42 locations incl. Anchorage
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT07063745·Phase 2, Phase 3·Recruiting